Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Carpenter

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAJeffrey C Thompson, Stephanie S Yee, Andrea B Troxel, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Pigment Cell & Melanoma Research|August 9, 2017
Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasmaTara C Gangadhar, Samantha L Savitch, Stephanie S Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2025
Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with GlioblastomaJacob E Till, Nicholas J Seewald, Zachariya Yazdani, et al.
Clinical and Translational Medicine|January 19, 2026
Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinomaJacob E Till, Ofer Gal-Rosenberg, Sophia G Giliberto, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAJeffrey C Thompson, Stephanie S Yee, Andrea B Troxel, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Pigment Cell & Melanoma Research|August 9, 2017
Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasmaTara C Gangadhar, Samantha L Savitch, Stephanie S Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2025
Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with GlioblastomaJacob E Till, Nicholas J Seewald, Zachariya Yazdani, et al.
Clinical and Translational Medicine|January 19, 2026
Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinomaJacob E Till, Ofer Gal-Rosenberg, Sophia G Giliberto, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Pageof 9